A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Oct 2015
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Therapeutic Use
- 15 Oct 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.
- 09 Dec 2014 Planned primary completion date changed from 1 Dec 2013 to 1 Jun 2015 as reported by ClinicalTrials.gov.
- 09 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.